Abstract

The present invention discloses a method for repairing or preventing retinal damage, which includes: administering a composition comprising a Lactobacillus plantarum PL-02 strain or a metabolite thereof to a subject in need thereof; wherein the PL-02 strain is deposited at the China General Microbiological Culture Collection Center with a deposition number CGMCC 20485.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/745 - Bifidobacteria
• A61P 27/02 - Ophthalmic agents
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus
• C12R 1/23 - Lactobacillus acidophilus
• C12R 1/25 - Lactobacillus plantarum

Abstract

A method for increasing calcium absorption includes administering to a subject in need thereof a composition containing a culture of Lactobacillus rhamnosus MP108. The Lactobacillus rhamnosus MP108 is deposited under the terms of the Budapest Treaty at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 21225.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 35/745 - Bifidobacteria
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus

Abstract

A method for increasing calcium absorption includes administering to a subject in need thereof a composition which contains a culture of Lactobacillus plantarum PL-02. The Lactobacillus plantarum PL-02 is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 20485 in accordance with the Budapest Treaty.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 35/745 - Bifidobacteria
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Abstract

A lactic acid bacterial composition for modulating immune cell differentiation and/or reducing pro-inflammatory cytokine secretion includes: (a) a Limosilactobacillus reuteri GL-104 strain; and (b) a Lacticaseibacillus rhamnosus F-1 strain; wherein the GL-104 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M209138, and the F-1 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M2011124. Additionally, a method for treating or preventing allergic rhinitis by administering the foregoing composition to a subject in need thereof is also provided.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Goods & Services

Albumin dietary supplements; Bacteriological preparations for medical and veterinary use; Vitamin preparations; Medicines for alleviating constipation; Laxatives; Nutritive substances for microorganisms for medical purposes; Dietetic foods adapted for medical purposes; Food for babies; Biological reagents for veterinary purposes; Dietary fiber for use as an ingredient in the manufacture of dietary supplements; Preparations of trace elements for human and animal use; Adjuvants for medical purposes; Food supplements, namely, anti-oxidants; Enzyme dietary supplements; Protein dietary supplements; Protein supplements for animals; Preparations of microorganisms for medical purposes; Nutraceutical preparations for therapeutic or medical purposes; Whey protein dietary supplements

Goods & Services

Albumin for industrial purposes; Protein for industrial use; Bacterial preparations, other than for medical and veterinary use; Bacteriological culture mediums, other than for medical or veterinary purposes; Cultures of microorganisms, other than for medical and veterinary use; Biological tissue cultures, other than for medical or veterinary purposes; Enzyme preparations for the food industry; Enzymes for the food industry; Milk ferments for the food industry; Milk ferments for industrial purposes; Casein for the food industry; Preparations of microorganisms, other than for medical and veterinary use; Vitamins for use in the manufacture of food supplements; Antioxidants for use in the manufacture of food supplements; Proteins for use in manufacture; Proteins for use in the manufacture of food supplements; Proteins for the food industry; Media for bacteriological cultures, other than for medical or veterinary purposes

Abstract

A method for increasing calcium absorption includes use of a composition containing a culture of Bifidobacterium longum subsp. infantis BLI-02 which is deposited under the Budapest Treaty at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 15212.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• C12N 1/20 - BacteriaCulture media therefor

Abstract

A method for increasing calcium absorption includes administering to a subject in need thereof a composition containing a culture of Bifidobacterium animalis subsp. lactis CP-9. The Bifidobacterium animalis subsp. lactis CP-9 is deposited under the Budapest Treaty at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2014588.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Goods & Services

Production of probiotic powder under customer specifications; freezing of foods; foods preservation; foods and drink preservation; food ingredients preservation

Abstract

Lactobacillus paracasei ET-66 strain.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 31/04 - Antibacterial agents

Abstract

lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria

Abstract

lactis CP-9 which is deposited at the CCTCC under an accession number CCTCC M 2014588.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Bifidobacterium longum BLI-02 strains. The present invention further provides a method for preventing aging by administering the foregoing anti-aging composition to a subject in need thereof.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61Q 19/08 - Anti-ageing preparations
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/225 - Lactobacillus

Abstract

Escherichia coli, the method including the step(s) of: administering the foregoing lactic acid bacterial composition to a subject in need thereof. The present invention additionally provides a method for treating or preventing jaundice, the method including the step(s) of: administering the foregoing lactic acid bacterial composition to a subject in need thereof.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 35/745 - Bifidobacteria
• A61N 5/06 - Radiation therapy using light
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61P 31/04 - Antibacterial agents

Abstract

lactis CP-9 deposited at the CCTCC under an accession number CCTCC M 2014588, in a ratio of colony forming units which ranges from 1:0.125:0.125 to 1:8:8. Use of the probiotic culture for improving skin condition and for inhibiting pathogenic infection is also provided.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents

Goods & Services

perfumeries; essential oils; cosmetics; toothpaste; non-medicated cleaning preparations for the teeth; cosmetic preparations, namely, perfumes; cosmetics for animals

Goods & Services

Dishwashing detergent; kitchen cleaners; impregnated cloths for polishing; polishing preparations; grinding preparations; perfumeries; essential oils; cosmetics; toothpaste; cleaning preparations for the teeth; fumigation preparations [perfumes]; cosmetics for animals; air fragrance preparations.

Abstract

infantis BLI-02 deposited at the CGMCC under CGMCC 15212.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 1/36 - Adaptation or attenuation of cells
• C12R 1/23 - Lactobacillus acidophilus
• C12R 1/25 - Lactobacillus plantarum

Abstract

Lactobacillus paracasei MP137 which is deposited at the CGMCC under an accession number CGMCC 21224.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 31/04 - Antibacterial agents
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/225 - Lactobacillus
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

A composition, which comprises at least one of an AP-32 strain of Lactobacillus salivarius subsp. salicinius, a BLI-02 strain of Bifidobacterium longum subsp. infantis and fermentation metabolites thereof, has a physiological activity of elevating ability of brain tissue. The present invention may be used in form of a food composition or a pharmaceutical composition to elevate the ability of brain tissue.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Lactobacillus casei CS-773 strain, and a physiologically acceptable excipient, diluent, or carrier. All of the strains are deposited at the China General Microbiological Culture Collection Center.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/04 - AnorexiantsAntiobesity agents
• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria

Abstract

lactis CP-9 ranges from 1:0.1:0.1 to 1:1:8. Also disclosed herein is use of the probiotic composition for alleviating type 1 diabetes mellitus (T1DM).

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/225 - Lactobacillus

Abstract

Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection under an accession number CCTCC M 2011127, and combinations thereof.

IPC Classes  ?

• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12N 1/20 - BacteriaCulture media therefor
• C12P 39/00 - Processes involving microorganisms of different genera in the same process, simultaneously
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12R 1/23 - Lactobacillus acidophilus
• C12R 1/25 - Lactobacillus plantarum

Goods & Services

Mineral food supplements; nutritional supplements in the nature of a nutrient-dense, protein-based drink mix; protein dietary supplements; food supplements, namely, anti-oxidant; powdered nutritional supplements drink mix containing protein; nutritional supplements, namely, probiotic compositions; vitamin and mineral supplements; dietary fiber for use as an ingredient in the manufacture of dietary supplements; nutritional supplements; plant extracts for medical,veterinary and pharmaceutical purposes; enzyme dietary supplements; casein dietary supplements; cultures of microorganisms for medical or veterinary use; infant formulas; foods for babies.

Abstract

Lactobacillus plantarum TSP05 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 16710.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• C12N 1/20 - BacteriaCulture media therefor
• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• C12R 1/25 - Lactobacillus plantarum

Abstract

Lactobacillus plantarum LPL28, which can efficiently increase the amount of oral IgA and/or inhibit the oral pathogens, and thus have a potential to prevent teeth cavities and/or periodontal diseases.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• C12N 1/20 - BacteriaCulture media therefor
• A61P 31/04 - Antibacterial agents
• C12R 1/25 - Lactobacillus plantarum

Abstract

A probiotic for preparing a composition for improving oral immunoglobulin A content and inhibiting oral pathogens and a use, wherein the probiotic comprises Lactobacillus plantarum LPL28 as an active ingredient, and can effectively improve oral IgA content and/or inhibit oral pathogens, thereby having the potential for preventing dental caries and/or periodontal diseases.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A61K 6/00 - Preparations for dentistry
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

longum OLP-01 that is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17345. Also disclosed herein are use of at least one of the abovementioned lactic acid bacterial strains for treating obesity and/or an obesity-related disorder, and for inhibiting fat absorption.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

Lactobacillus reuteri).

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 13/00 - Drugs for disorders of the urinary system

Abstract

Lactobacillus acidophilus TYCA06, which are respectively deposited at the Bioresource Collection and Research Center (BCRC) under accession numbers BCRC 910437, BCRC 910645 and BCRC 910813. Also disclosed is a method for promoting defecation, including administering to a subject in need thereof an effective amount of the composition.

IPC Classes  ?

• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
• A61P 1/10 - Laxatives
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

infantis BLI-02 strain.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/10 - Laxatives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt

Abstract

Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

An isolated lactic acid bacteria strain: Bifidobacterium longum subsp. longum OLP-01 strain for increasing exercise performance and ameliorating fatigue is disclosed. A variety of animal experiments have proved that OLP-01 not only effectively improves muscle strength and swimming endurance but also significantly reduces fatigue-related biochemical indicators, including blood lactate, blood urea nitrogen and the activity of creatine kinase.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 21/06 - Anabolic agents
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

IPC Classes  ?

• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A23C 19/032 - Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
• A23C 19/06 - Treating cheese curd after whey separationProducts obtained thereby
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Goods & Services

Preparations of microorganisms for medical use; protein supplements; protein dietary supplements; antioxidant for nutritional supplements; protein powder dietary supplements; protein nutritional additives; LAB extract nutritional supplements; vitamin and mineral supplements; nutritional supplements; nutritional supplements for medical use; vitamin supplements; enzyme dietary supplements; dietetic foods adapted for medical purposes; enzyme food supplements; enzyme nutritional supplements; food supplements for infants; medicated supplements for foodstuff for babies; food for babies; dietary supplements for infants.

Goods & Services

Mineral food supplements; nutritional supplements in the nature of a nutrient-dense, protein-based drink mix; protein dietary supplements; food supplements, namely, anti-oxidant; powdered nutritional supplements drink mix containing protein; nutritional supplements, namely, probiotic compositions; vitamin and mineral supplements; dietary fiber for use as an ingredient in the manufacture of dietary supplements; nutritional supplements; plant extracts for medical, veterinary and pharmaceutical purposes; enzyme dietary supplements; casein dietary supplements; cultures of microorganisms for medical or veterinary use; infant formula; food for babies

Abstract

Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Abstract

Bifidobacterium bifidum, and combinations thereof.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61L 29/00 - Materials for catheters or for coating catheters
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof

Goods & Services

Microbial preparations for medical use; Protein supplements; Protein dietary supplements; Nutritional supplements, namely, antioxidants; Protein powder dietary supplements; Dietary supplements, namely, protein nutritional additive; Lactic acid bacteria extract nutritional supplements; Vitamin and mineral supplements; Nutritional supplements; Nutritional supplement for medical use; Vitamin supplements; Enzyme food supplements; Enzyme dietary supplements; Food for babies; Dietary supplements for infants; Medicated supplements for foodstuffs for babies

Abstract

Lactobacillus rhamnosus CT-53 (CCTCC stock No. M2011129) or combinations thereof. The present invention may inhibit TNF-α secretion and promote IL-10 secretion of dendritic cells and therefore inhibit inflammation, particularly inflammation of vagina mucosa cells. The present invention may be presented as oral probiotics and direct-use vagina probiotics.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;